Piper Jaffray Remains Sidelined as Cost Cuts Drive ITT Educational Services' (ESI) EPS Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Stock Movers 03/14: (CPXX) (SZYM) (ESI) Higher; (IMMU) (MNKD) (NVIV) Lower (more...)
March 14, 2016 6:09 PM EDTCelator Pharmaceuticals, Inc. (Nasdaq: CPXX) 373% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.
Solazyme, Inc. (Nasdaq: SZYM) 29.5% HIGHER; has signed a definitive multi-year global supply agreement with Unilever.... More
ITT Educational Services (ESI) Posts Q4 EPS of $0.44; Will Restate Certain Financials
March 14, 2016 4:44 PM EDTITT Educational Services (NYSE: ESI) reported Q4 EPS of $0.44, $0.26 better than the analyst estimate of $0.18. Revenue for the quarter came in at $202.4 million versus the consensus estimate of $203.3 million.
Based on various assumptions, including the historical and projected performance and collection of the student loans held by the PEAKS Trust and the CUSO, the company reported that its current estimate of the payments it may have to make under the PEAKS guarantee and the CUSO risk sharing agreement (the "CUSO RSA"), in the aggregate, are approximately:
$27.7 million in 2016;
$13.1 million in 2017;
$13.4 million... More
